"There are some kinks to be worked out, for sure," Bill Forrester agreed with the group of men and women around him. "Side effects, bodily responses, more accurate predictions, et cetera, et cetera. But we're not going to be able to isolate the secondary responses to the deuterotone without further testing."
"Meaning...?" This came from Ken Hastings, Forrester's direct superior and the chief operating officer of Connecticut Pharmaceuticals, in its entirety. He was a balding man, in his mid-fifties, a bit pudgy like Forrester himself. And, over the course of the previous few weeks, he'd been playing devil's advocate to those who had been short-of-breath due to the excitement of Erica Rivers's experiment.
"Meaning," Jake Rinaldi interjected, "that we won't be able to isolate whether the concomitant is an individual psychological response to unrelated stimuli, or an effect of the deuterotone itself, without moving forward with Phase One trials."
Rinaldi was the most junior executive in the room, a vice president in a throng of executive vice presidents, senior vice presidents, and members of the Board. He was, however, Forrester's right-hand man, with direct responsibilities for the Human Hormones Lab, among other things. It was Rinaldi who worked directly with lead scientists, research principals, and β in this case β with Dr. Natalie Hart, director of the Human Hormones Lab itself. Thus, Rinaldi was perhaps the most informed person in the room, aside from maybe the peroxide blonde technician behind the ops desk, or the naked scientist writhing on the floor behind him.
There were fifteen men and women in all - not including Wendy Milne, who watched the group with disinterest from the far side of the room. Forrester had assembled the Board of Directors and all of management that Monday evening, leading them down to ConnPharm's state-of-the-art data collection device, the Bullpen. The Executive Vice President of Corporate Strategy, the Senior Vice President of Sales and Marketing, the Senior Vice President of Finance, the Chief Medical Officer, ConnPharm's General Counsel, Hastings the COO, and even Andrew Donnelly, the Chairman, President, and CEO, stood before him, peering through the one-way glass at the dark-haired woman confined to the Bullpen. They were joined by the seven members of the Board, six men and one woman, all of whom seemed enthralled in the peep show to which they were being indulged.
Erica Rivers could have perhaps better explained the science behind her recent breast augmentation, but Rinaldi had kept the group's visit from the scientist, and had instructed Wendy Milne to do the same. There were concerns about Erica's erratic behavior over the past few weeks, and Rinaldi had doubted that the girl would be able to divorce herself from the various perversions she had wallowed in to adequately respond to the queries of management and the Board.
Even now, despite being entirely unaware of the twelve men and three women on the other side of the mirror glass, Erica was on her knees, bent over and supporting herself on her left elbow, with her posterior in the air. Her right hand was moving rapidly back and forth between her legs, and it was clear to all present that the girl was both gasping for air and moaning with gratification. Thankfully to some, and perhaps disappointingly to others, Erica remained facing the wall to the left of the Bullpen, meaning her left leg blocked a direct vista of her vagina itself. Her forehead was resting against her left forearm, inches from the plastic keyboard she'd been heavily engaged with just minutes earlier.
Projected onto the wall were a series of biochemical structures, hardly pornographic, hardly arousing. Forrester and Rinaldi had both warned their audience that they might be exposed to "questionable" content being projected in the Bullpen, but Erica hadn't needed visual depictions of nudity and sex to start masturbating sixteen days earlier, and she apparently didn't need them now, either.
"Shouldn't the deuterotone be out of her system by now?" Michael Yamamoto, the Chief Medical Officer, asked quizzically. His eyes remained fixed on the black-haired woman before him, but he seemed to be looking at her as a puzzle, and not as sexual object. Yamamoto had mostly been detached from the deuterotone project, though his underlings in Medical Oversight had nearly shut it down. He, like many in ConnPharm's upper management, had doubted the results of Dick Abbott's report β it seemed less likely that sweet, conservative Erica Rivers had been masking a vulgar exhibitionist streak all these years, and more likely that she was simply reacting to the drugs in her system. But the deuterotone had run its course, and after the girl's final injection seven days earlier, the compound should have been flushed.
Which left Yamamoto, among others, to begin wondering if Dick Abbott's report was indeed correct.
"There are trace amounts," Rinaldi conceded, but it was clear from his answer, and his tone, that even he had begun to believe that Erica's behavior was psychologically-induced, and not thrust upon her by foreign chemistry. He added, "And I should note that, even in the week following Dr. Rivers's first injection, the level of deuterotone in her system was no higher than the level of testosterone in the bodies of each and every man in this room."
"So she's a...?" Jane Allard, the head of sales and marketing, obviously wanted to finish the question with a range of choice words, from slut, to whore, to nymphomaniac, but she instead just let her voice trail off.
"She was a poor choice for this early analysis," Rinaldi answered, diplomatically, "given the amount of exposure she has undergone, and given what sort of personality quirks may or may not have existed in the recesses of her subconscious."
"On the one hand," Forrester stepped in, "we have twelve years worth of trials and experiments on rats and rabbits and chimps. We have a mountain of data, and any number of models that should predict side effects in the human body. On the other, we have one early analysis, performed upon a woman who might very well be battling her own inner demons and repression."
"But the science works," Donnelly said flatly. He had been quiet for much of the expedition into the Observation Room, taking in the beautiful girl that was hunched over on the clinically white floor of the Bullpen. Her paced had lessened, and the heaving of her chest had slowed with it. If she'd hadn't just orgasmed and was coming down, than she was slowly building to her climax.
"The science works," Forrester agreed. "We overshot the model a bit, but individual body chemistry is always going to prevent us from being exact."
Donnelly raised an eyebrow.
"She was shooting for a D-cup, Andrew," the head of research and development explained. "She's a double D."
"From a B-cup?" Harriet Vanoza asked. She was a member of the Board, a successful biochemistry professor at the state's university in Storrs.
Forrester nodded.